scholarly journals Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer

2021 ◽  
pp. 397-402
Author(s):  
Kazuhiro Kitajima ◽  
Shingo Yamamoto ◽  
Masataka Ikeda ◽  
Takashi Yamasaki ◽  
Yusuke Kawanaka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Somatostatin Receptor ◽  
Prostate Tumor ◽  
Somatostatin Receptor Scintigraphy ◽  
Resected Specimen ◽  
Weighted Image ◽  
Pet Ct ◽  
Receptor Scintigraphy ◽  
Fdg Pet Ct

Treatment-related neuroendocrine-differentiated prostate cancer (NEPC) is a rare tumor entity that transdifferentiates from adenocarcinoma as an adaptive response to androgen receptor pathway inhibition. We report a 79-year-old male with treatment-related NEPC, presenting as rectal bleeding after hormonal therapy. MRI showed a 51 × 52 × 65 mm tumor occupying almost the whole prostate gland and invading the seminal vesicle and rectum as moderately heterogeneous hypointensity on T2-weighted image, restricted diffusion on apparent diffusion coefficient map and diffusion-weighted imaging, and heterogeneous enhancement on Gd-enhanced T1-weighted image. FDG-PET/CT showed strong FDG uptake of the prostate tumor, and somatostatin receptor scintigraphy (SRS) showed mild uptake of the prostate tumor. The surgically resected specimen revealed NEPC. If prostate cancer worsens despite conventional therapy, treatment-related NEPC should be considered, and the benefit of imaging examinations including prostate MRI, FDG-PET/CT, and SRS is in localizing lesions with neuroendocrine differentiation.

scholarly journals FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer

2011 ◽  
Vol 36 (10) ◽  
pp. 961-962 ◽  
Author(s):  
Bhushan Desai ◽  
Wafaa Elatre ◽  
David I. Quinn ◽  
Hossein Jadvar
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Pancreatic Metastasis ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Sowon Oh ◽  
Vikas Prasad ◽  
Dong Soo Lee ◽  
R. P. Baum
Keyword(s):  
Glucose Metabolism ◽  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Receptor Expression ◽  
Peptide Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct

The heterogeneous nature of the neuroendocrine tumors (NET) makes it challenging to find one uniformly applicable management protocol which is especially true for diagnosis. The discovery of the overexpression of somatostatin receptors (SMS-R) on neuroendocrine tumor cells lead to the generalized and rapid acceptance of radiolabeled somatostatin receptor analogs for staging and restaging of NET as well as for Peptide Receptor Radionuclide Therapy (PRRNT) using Y-90 and Lu-177 DOTATATE/DOTATOC. In this present work we tried to look in to the effect of PRRNT on the glucose metabolism assessed by F-18 FDG PET/CT and SMS-R density assessed by Ga-68 DOTANOC PET/CT. We observed a complex relationship between the somatostatin receptor expression and glucose metabolism with only 56% (77/138) of the lesions showing match, while the others show mismatch between the receptor status and metabolism. The match between receptor expression and glucose metabolism increases with the grade of NET. In grade 3 NET, there is a concurrence between the changes in glucose metabolism and somatostatin receptor expression. PRRNT was found to be more effective in lesions with higher receptor expression.

scholarly journals Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

2019 ◽  
Vol 8 (7) ◽  
pp. 1032 ◽  
Author(s):  
Luciano Carideo ◽  
Daniela Prosperi ◽  
Francesco Panzuto ◽  
Ludovica Magi ◽  
Maria Sole Pratesi ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Gamma Camera ◽  
Somatostatin Receptor ◽  
Clinical History ◽  
Receptor Imaging ◽  
Prognostic Information ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) receptors (SSTR) on cell surface, especially G1 and G2 stage tumors, but they can show a dedifferentiation in their clinical history as they become more aggressive. Somatostatin receptor imaging has previously been performed with a gamma camera using [111In]In or [99mTc]Tc-labelled compounds, while [68Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. Moreover, in the last few years 18F-fluorodeoxyglucose ([18F]FDG) PET/CT has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information, particularly when coupled with [68Ga]Ga-labelled SST analogues PET/CT. This review focuses on the importance of combined imaging with [68Ga]Ga-labelled SST analogues and [18F]FDG for the management of GEP-NENs.

FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis

2020 ◽  
Vol 8 (5) ◽  
pp. 365-375
Author(s):  
Felipe Alves Mourato ◽  
Maria Amorim Almeida ◽  
Ana Emília Teixeira Brito ◽  
Aline Lopes Garcia Leal ◽  
Paulo Almeida Filho ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Somatostatin Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document